遗传性出血性毛细血管扩张症合并房颤的风险管理:抗血栓与抗纤溶治疗的权衡
本文回顾性分析了33例遗传性出血性毛细血管扩张症(HHT)合并房颤(AF)患者,评估抗凝(AC)、抗血小板(AP)及氨甲环酸(TXA)治疗的耐受性。结果显示,AC治疗13例中62%因出血提前停药,AP治疗9例中33%因鼻出血停药,而TXA治疗11例平均16.6个月无血栓事件。提示该人群抗血栓治疗常被 withheld 或中断,而TXA可能安全耐受。
要点
- HHT合并AF患者抗凝治疗因出血停药率高(62%)。
- 抗血小板治疗因鼻出血停药率为33%。
- 氨甲环酸平均使用16.6个月未观察到血栓事件。
核心结论
- HHT合并AF患者中抗血栓治疗常被 withhold 或中断,而氨甲环酸可能安全耐受。
研究设计与样本
- 回顾性综述33例HHT合并AF患者,评估AC、AP及TXA治疗的耐受性。
主要发现
- AC治疗13例,62%因出血需提前停药。
- AP治疗9例,33%因鼻出血停药。
- TXA治疗11例,平均16.6个月无血栓事件;6例因AF相关顾虑未处方TXA。
临床怎么用
- 对HHT合并AF患者,处方抗血栓治疗需充分评估出血风险,TXA或可作为替代选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hereditary hemorrhagic telangiectasia (HHT) is characterized by mucocutaneous telangiectasias and arteriovenous malformations, often complicated by chronic epistaxis. Patients with HHT and comorbid atrial fibrillation (AF) present a clinical challenge in the concurrent management of bleeding and clotting risks. We retrospectively reviewed HHT patients with AF to evaluate the tolerability of anticoagulant (AC), antiplatelet (AP), and TXA therapies. Of 33 patients, AC was attempted in 13 cases, with 62% requiring premature discontinuation due to bleeding. AP therapy was initiated in 9 patients, with 33% discontinued due to epistaxis. Fourteen patients who met criteria for AC/AP were not prescribed them due to bleeding concerns. TXA was administered in 11 patients for a mean of 16.6 months with no thrombotic events; 6 were not prescribed TXA due to AF-related concerns. Our findings suggest that antithrombotic therapy for AF is frequently withheld or discontinued in this population, while TXA may be safely tolerated.
引用
- Adelman AE, Richardson L, Jackson L, et al. Navigating Risk in Atrial Fibrillation and Hereditary Hemorrhagic Telangiectasia: Antithrombotic Versus Antifibrinolytic Therapy. Otolaryngol Head Neck Surg. 2026. PMID: 41793285. doi:10.1002/ohn.70187
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。